Europe Advances the Transcaval Approach for TAVR

The transfemoral access is clearly the preferred approach to transcatheter aortic valve replacement (TAVR), followed by the trans-axillary or trans-subclavian. Despite the alternatives, some patients are still ineligible.

trans cava

This study recently published in EuroIntervention reports initial experiences in Europe with the transfemoral transcaval approach. 

It included 50 patients from 5 centers assessed according to the VARC-2 definitions. all Patients presented high surgical risk and mean age was 78.7 ± 8.0 years (mean STS 6.1%).

The transcaval was successful in 49 of the 50 patients and the valve was successfully implanted in 94% of cases. Sealing of the aortic-cava puncture with a nitinol occluding device was successful in all cases with no need for emergency surgery. Only one patient was treated with a coated stent at aortic puncture level 24 hrs. after procedure due to a gradual hemoglobulin drop of (3 g/dl).


Read also: Cath Lab Management Protocol for the COVID-19 Outbreak.


VARC-2 life threatening bleeding and major vascular complications occurred in 4% and 10% of cases, respectively, for the transcaval access.

There were no cases of bleeding or vascular complications after discharge.

Conclusion

The transcaval approach proved to be feasible and safe for TAVR in high surgical risk patients with severe aortic stenosis that were not eligible for the conventional transfemoral approach or alternatives such as the trans-axillary or trans-subclavian. 

Original title: Feasibility and safety of transcaval transcatheter aortic valve implantation: a multicentre European registry.

Reference: Giulia Costa et al. EuroIntervention 2020;15:e1319-e1324.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...